Contents lists available at ScienceDirect



Clinical Neurology and Neurosurgery



journal homepage: www.elsevier.com/locate/clineuro

Review Article

Gender differences in mortality of hospitalised stroke patients. Systematic review and meta-analysis



Abdel-Rahman Abdel-Fattah^{a,*}, Tiberiu A. Pana^a, Toby O. Smith^b, Zahra Pasdar^a, Maha Aslam^a, Mamas A. Mamas^c, Phyo K. Myint^a

^a Ageing Clinical and Experimental Research (ACER) Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK

^b Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

^c Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK

ARTICLE INFO

Keywords: Stroke Ischaemic stroke Haemorrhagic stroke Mortality Gender differences

ABSTRACT

Objective: Gender differences in mortality after stroke remains unclear in the current literature. We therefore aimed to systematically review the gender differences in mortality up to five years after ischaemic (IS) or haemorrhagic stroke (HS) to address this evidence gap.

Methods: The literature was systematically searched using Ovid EMBASE, Ovid Medline, and Web of Science databases, from inception-November 2021. The quality of evidence was appraised using the CASP Cohort-study checklist. Unadjusted and adjusted odds and hazard ratios were meta-analysed, separately for IS and HS and a subgroup analysis of age-stratified mortality data was conducted.

Results: Forty-one studies were included (n = 8,128,700; mean-age 68.5 yrs; 47.1% female). 37 studies were included in meta-analysis (n = 8, 8008, 110). Compared to men, women who had an IS had lower mortality risk in-hospital (0.94; 95%CI 0.91–0.97), at one-month (0.87; 95%CI 0.77–0.98), 12-months (0.94; 95%CI 0.91–0.97) and five-years (0.93 95%CI 0.90–0.96). The subgroup analysis showed that this gender difference in mortality was present in women \geq 70 years up to one-month post-IS (in-hospital: 0.94; 95%CI 0.91–0.97; one-month: 0.87; 95% CI 0.77–0.98), however, in women < 70 years this difference was no longer present.

Nevertheless, analysis of crude data showed women were at higher risk of mortality in-hospital, at 12-months and five-years (in-hospital: 1.05; 95%CI 1.03–1.07, 12-months: 1.10; 95%CI 1.06–1.14, five-years: 1.06; 95% CI 1.02–1.10). After HS, women had higher mortality risk in-hospital (1.03; 95%CI 1.01–1.04) however, no gender differences were found post-discharge.

Conclusion: The gender differences in post-stroke mortality differ by stroke type, age group and follow-up. Crude stroke mortality in women is higher than in men and this appears to be driven by pre-existing comorbidities. In adjusted models, women have a lower mortality risk following IS, independent of duration of follow-up. After HS, women had higher mortality in hospital however, no gender differences after hospital discharge were found.

1. Introduction

There is a growing emphasis on understanding the epidemiology of gender differences in outcomes following a stroke. Stroke remains a worldwide public health concern and is now recognised as the leading cause of long-term disability [1]. Women have higher incidence of stroke than men as well as worse stroke outcomes, which may be attributed to poorer pre-stroke function, older age, and higher prevalence of atrial fibrillation (AF) [2]. More recent literature has emphasised the major influence of confounders such as age, prevalence of AF and poorer premorbid status suggesting that women are less likely to die after a stroke compared to men after adjusting for confounders [3, 4]. This is not uniformly observed across the geographical regions or ethnicities, with two large observational studies form North America suggesting that no gender differences exist in stroke mortality regardless of follow-up time-period [4,50,51]. In contrast, some studies from

https://doi.org/10.1016/j.clineuro.2022.107359

Received 22 February 2022; Received in revised form 22 June 2022; Accepted 3 July 2022 Available online 6 July 2022

0303-8467/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

^{*} Correspondence to: School of Medicine, Medical Sciences and Nutrition, Rooms 1.129/1.130, West Block, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK.

E-mail address: a.abdelfattah.17@abdn.ac.uk (A.-R. Abdel-Fattah).

Southeast Asia and the Indian subcontinent reported higher stroke mortality in women compared to men [3,52,53].

Understanding the gender differences in stroke mortality is of paramount importance to epidemiologists, clinicians and healthcare industries as this understanding may form the basis for the development of gender-specific stroke prevention and management. As a result, this would improve outcomes of stroke in women and reduce its dominant burden on disability-adjusted-life-years (DALYs) worldwide.

We aimed to undertake a systematic review and meta-analysis to assess the gender differences in stroke-type specific mortality at multiple time points from admission through hospital discharge to five-years follow up. We also carried out an exploratory subgroup analysis stratified by age group (mean age <70 years and \geq 70 years) to investigate whether age influences gender differences in stroke mortality.

2. Methods

A systematic review and meta-analysis of RCTs was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement guidance [5].

2.1. Search strategy

Two authors selected studies reporting gender differences in mortality of hospitalised stroke patients by independently carrying out a literature search of the following databases: Ovid MEDLINE, Ovid EMBASE and Web of Science, from inception to November 2021. Detailed search strategy is shown in Supplementary File 1. The articles searched were confined to English-language only. A manual search of reference lists of relevant reviews and their included studies was also performed.

2.2. Eligibility and study selection

The inclusion criteria for the studies included observational studies in English with adult participants > 18 years hospitalised due to stroke. Studies which stratified their data by stroke type (IS or HS) were analysed. Strokes of unspecified type (SUT) were also pooled for metaanalysis where appropriate. No limitations on geographical location were applied. Studies which analysed animal subjects or were conference abstracts or poster presentations were excluded. Similarly, studies reporting patients with non-stroke diagnoses such as those with transient ischaemic attacks (TIAs) were also excluded.

2.3. Data extraction

Two authors independently screened titles and abstracts [anonymous]. Potentially relevant studies were reviewed together to ascertain their eligibility. The final study selection and data extraction of the included studies were performed by the same two authors, then reviewed and verified by a third author. The extracted data included

Table	1

Characteristics of included studies.

basic study characteristics including: mean age, proportion of females, country of origin, follow-up time frame and co-morbidities. Primary authors of all eligible studies were contacted to request any missing data.

2.4. Bias assessment

Bias assessment of the included studies was performed by two authors independently using the CASP Cohort tool (Table 2).

2.5. Data synthesis and outcome measure

Unadjusted and adjusted odds, hazard and risk ratios for in-hospital, one-month, 12-months and five-years mortality were pooled using the generic inverse variance method using fixed-effects model in RevMan 5.4 software. Study heterogeneity was assessed by evaluating the population characteristics and observed value of I^2 , to determine which studies were appropriate to pool. Data with sufficient homogeneity were included in the meta-analysis. The primary outcome was risk of mortality in women compared to men as the baseline after IS, HS or SUT. The outcome of interest was assessed at the following follow-up time periods: in-hospital, up to one month, up to 12-months and up to fiveyears. Due to heterogeneity in risk reporting; odds ratio (OR), hazard ratio (HR) and risk ratios (RR) were all meta-analysed together and results expressed as 'risk', since mortality is a rare event. Descriptive and analytical epidemiological findings were synthesised from separate analyses of unadjusted (crude) and adjusted data, respectively. Whenever studies reported more than one result within an individual time bracket (e.g. three months and six months data) priority was given to the longerterm follow up (e.g. six months).

Mortality data for women and men stratified by age were collated where available to facilitate for an exploratory subgroup analysis stratified by age group. Mean age of study cohort was used where agestratified data was not available. The age brackets: < 70 years and \geq 70 years, were chosen based on literature suggesting that elderly patients over 70 years have a different aetiology and epidemiology of stroke mortality [53].

3. Results

3.1. Search results

Forty-one studies were included in the systematic review (n = 8,128,700; mean age 68.5 years; 47.1% female) and 36 studies were deemed appropriate for meta-analysis (n = 8,008,110). The PRISMA flowchart can be found in Supplementary Fig. 1. Justification for exclusion of papers (n = 4) is detailed in Supplementary Table 2.

3.2. Characteristics of included studies

The characteristics of the included studies are presented in Table 1.

Characteristics of	included stud						
Papers (N = 41)	Population (N = 8 128,700)	% female (Mean %= 47.1)	Mean female age (years) (Mean= 68.7 yrs)	Mean male age (yrs) (Mean= 68.2 yrs)	Region	Time points for mortality	Co-morbidities
Bonkhoff, 2021	761,106	48.0	75.3	69.4	Germany	In-hospital mortality	Age, diabetes mellitus (DM), hypertension (HTN), atrial fibrillation (AF), ischaemic heart disease (IHD), previous stroke, hypercholesterolaemia (HL), stroke severity using NIHSS scale and pre-stroke functional status
Eriksson, 2021	335,183	48.3	78.1	73.3	Sweden	7, 28 and 90 days	Age, DM, smoking, HTN, AF, previous stroke
Irie, 2021	17,956	41.3	n/a	n/a	Japan	30 days	Age and stroke severity

Table 1 (continued)

Papers (N = 41)	Population (N = 8 128,700)	% female (Mean %= 47.1)	Mean female age (years) (Mean= 68.7 yrs)	Mean male age (yrs) (Mean= 68.2 yrs)	Region	Time points for mortality	Co-morbidities
Phan, 2021	9441	46.0	78.8	72.0	Australasia	1 year	Age, stroke severity. Comorbidities: dementia, HTN, smoking, HL, AF, HF, renal disease, liver disease, COPD, DM and cancer
Uchida, 2019	2399	45.3	79.7	72.8	Japan	90 days	Age, past and current smoker, HTN, DM, AF, history of stroke, pre-modified Rankin scale (mRS), baseline NIHSS score, baseline blood glucose, baseline LDL cholesterol and baseline creatinine
Weber, 2019	1,112,570	48.9	74.0	74.0	Germany	In-hospital mortality	Not stated
James, 2017	192,826	48.9	75	67	USA and Canada	In-hospital mortality	Race, AF, transient ischaemic attack (TIA) or stroke, coronary artery disease (CAD), myocardial infarction (MI), carotid stenosis, DM, HTN, peripheral vascular disease (PVD), dyslipidemia, smoking, international normalised ratio (INR), glucose, systolic blood pressure (SBP), creatinine, prior anti-platelet and/or anti-coagulant use, region, number of beds and hospital type, annual intracerebral haemorrhage (ICH) volume, rural location, The Joint Commission Primary Stroke Center Status
Mapoure, 2017	818	44.4	62.3	58.4	Cameroon	In-hospital mortality	AF, DM, stroke history
Ong, 2017	4278	41.1	72.2	69.9	Taiwan	In-hospital mortality	AF, DM, stroke history
Renoux, 2017	2553	50.6	76.5	71.4	United Kingdom	1 year	Age, HTN, DM, angina, MI, PVD, CHF, prior TIA/stroke, HL, VHD, cancer, VTE, dementia, current and past smokers and migraine
Xing, 2017	1325	32.3	63.1	59.1	China	3, 12 and 36 months	HTN, AF, DM, stroke history
Hsieh, 2016 Dehlendorff, 2015	1196 79,617	42.5 47.2	66.3 74.4	62.2 69.5	Singapore Denmark	30 days 7 and 30 days	HTN, DM, HL HTN, AF, DM, stroke and alcohol history and intermittent arterial claudication
Li, 2015	810	44	> 75	> 75	China	12 and 36 months	Age, stroke type, HTN, AF, DM, dyslipidemia, stroke history, anaemia, HF, rehabilitation, chronic kidney disease (CKD)
Talebi, 2014	341	56.0	69.9	67.7	Iran	7 days	HTN, DM, HL, IHD
Zhou, 2014	615	35.8	63.5	62.7	China	3, 6 and 12 months	HTN, AF, HL
Denti, 2013	1993	49.5	76.9	71.4	Italy	1 month	Age, stroke severity and premorbid disability
Ganti, 2013	245	51	77	69	Worldwide	7 days	HTN, AF, DM, stroke and alcohol history
Koton, 2013	5034	45.4	73.3	68.7	Israel	In hospital mortality and 3 months	Age, prior disability, modified Rankin Scale, NIHSS score, prior stroke, CHD, previous acute coronary syndrome (ACS) or HF, HTN, DM, HL, AF, Dyslipidemia, IHD, cancer, PAD and smoking
Santalucia, 2013	367	48.2	77.2	72.3	Italy	In-hospital mortality	AF, HTN, dyslipidemia, DM, obesity, TIA, AF The results were adjusted for age alone.
Lewsey, 2012	157,639	55	74	69	Scotland	30 days	Admission and socioeconomic deprivation. Comorbidities: DM, cancer, respiratory disease, HF, PVD, AF, HTN, renal failure, CAD, rheumatic/valvular heart disease, venous thromboembolism (VTE), depression, parkinsonism, dementia, falls and fractures and alcohol misuse.
Park, 2012	6635	42.7	70	64	Korea	In-hospital mortality	HTN, previous IHD and previous stroke
Olsen, 2012	26,818	48.5	73.9	68.9	Denmark	3 months	HTN, AF, DM, stroke and alcohol history and intermittent arterial claudication
Watila, 2012	91	33.0	55.6	56.2	Nigeria	30 days	HTN, AF, DM and Human immunodeficiency virus (HIV) infection
Wu, 2012	103,689	46.7	73.4	68.8	Hong Kong	30 days	Age, year of hospitalisation
DeVries, 2011	15,806	51.6	75	75	USA	30 days	AF, HF, CKD and anaemia
Ovbiagele, 2011	2,553,742	> 84	80.3	77.6	USA		Age, race, ethnicity, hospital region and location, stroke type and number of major procedures. Comorbidities: HF,

(continued on next page)

Table 1 (continued)

Papers (N = 41)	Population (N = 8 128,700)	% female (Mean %= 47.1)	Mean female age (years) (Mean= 68.7 yrs)	Mean male age (yrs) (Mean= 68.2 yrs)	Region	Time points for mortality	Co-morbidities
						In-hospital mortality (2005–2006)	MI, chronic pulmonary disease, cerebrovascular disease, hemiplegia, paraplegia, dementia, DM, malignancy, metastatic solid tumour, liver disease, peptic ulcer disease, PVD, renal disease and acquired immune deficiency syndrome (AIDS)
Towfighi, 2011	2,537,097	47.5	35–64 (no mean stated)	35–64 (no mean stated)	USA	In-hospital mortality	HF, MI, PVD, AIDS, DM, chronic pulmonary disease, cerebrovascular disease, hemiplegia/paraplegia, dementia, malignancy, metastatic solid tumour, liver disease, peptic ulcer disease, connective tissue disease and renal disease
Martinez- Sanchez, 2010	310	41.3	41.1	42.1	Spain	In-hospital mortality	Migraine, HTN, HL
Olsen, 2010	40,155	48.1	74.5	69.7	Denmark	1 week, 1 and 3 months, 1 year	HTN and cardiovascular risk factors
Wiszniewska, 2010	2534	54.4	74.3	68.8	Poland	30 days	HTN, HF, AF, TIA, CAD, DM and alcohol abuse
Oh, 2009	18,634	43.4	68.4	63.4	Korea	25 months	HTN, HL, AF
Palnum, 2009	29,549	63.1	> 80	> 80	Denmark	30 and 90 days	Age, civil status, type of residence, stroke severity, AF, HTN, DM, intermittent claudication, Charlson comorbidity index score, smoking, and alcohol intake and hospital department.
Olsen, 2009	25,607	45.3	72.6	68.5	Denmark	1 week	HTN, AF, DM, stroke and alcohol history, smoking, intermittent claudication, and previous stroke
Sweileh, 2009	186	51.1	68.7	69.5	Palestine	In-hospital mortality	Hypertension, diabetes, congestive heart failure, atrial fibrillation, ischaemic heart disease, smoking, recurrent stroke attack, chronic kidney disease, obesity
Vaartjes, 2009	30,675	51.9	72.9	69.3	Netherlands	1 and 5 years	AF, DM, and stroke history
Olsen, 2007	39,484	48.0	75.3	70.3	Denmark	7, 30, 90, 150 days	Alcohol, smoking, diabetes, HTN, AF, Intermittent arterial claudication
Andersen, 2005	999	56.0	77.0	70.9	Denmark	1, 5 and 10 years	HTN, IHD, AF, other disabling disease
Kapral, 2004	3323	46.0	73	69	Canada	In-hospital and 6 months	Age, Charlson comorbidity index score (of comorbidities), level of consciousness, stroke type, CNS score, hospital consent rate, marital status and living situation. Comorbidities: previous stroke, DM, HT, smoking, HL, AF, MI, Dementia
Di Carlo, 2003	4499	50.2	74.5	69.2	Europe	48 h and 3 months	HTN, AF, DM
Vemmos, 2000	555	44.4	76.1	75.1	Greece	1 year	Age, smoker, HT, HL, alcohol, DM, TIA, AF, MI, angina, CHF and VHD

The mean age in women was 75.3 years and 69.4 years in men. Sample populations of the included studies were from various regions world-wide including Germany [3,6], Sweden [7], Denmark [8–14], Japan [4, 15], Australia [16], North America [17], United States [18–20], Canada [21], Cameroon [22], Taiwan [23], China [24–26], Hong Kong [27], Singapore [28], Iran [29], Italy [30,31], Israel [32], Scotland [33], United Kingdom [34], Korea [35,36], Nigeria [37], Spain [38], Poland [39], Palestine [40], Netherlands [41], Greece [42], Di Carlo Europe [43] and worldwide [44].

3.3. Quality appraisal

Forty studies were analysed using the CASP cohort study tool (Table 2). One study had no full-text available therefore quality appraisal was not feasible [4]. All studies clearly addressed a research question (100%). Thirty-seven studies recruited the study cohort appropriately (92.5%), although only 34 studies measured mortality accurately (85%). Confounding was a major limitation as 30 studies identified confounders poorly (75%). One study did not have any access to information on confounding [6]. Data reported were overall precise in 34 studies (85%), however attrition bias may have been introduced due to incomplete follow-up data in 13 studies (32.5%).

3.4. Results of meta-analysis

3.4.1. Ischaemic stroke (IS)

Fifteen studies reported data on IS-specific mortality between women and men. Compared to men, analysis of adjusted data (Table 3) showed that women had lower mortality risk after IS at all time points, from in-hospital (Risk 0.94; 95% CI 0.91–0.97, n = 793,976) to one month (Risk 0.87; 95% CI 0.77–0.98, n = 20,040), 12 months (Risk 0.94; 95% CI 0.91–0.98, n = 63,255) and five years (Risk 0.93 95% CI 0.90–0.96, n = 31, 485) (Fig. 1).

When analysing crude data, women were at a higher risk of inhospital mortality (Risk 1.05; 95% CI 1.03–1.07, n = 903,223), up to 12 months (Risk 1.10; 95% CI 1.06–1.14, n = 81,889) and up to five years (Risk 1.06; 95% CI 1.02–1.10, n-50 119). In the immediate period after discharge and up to one-month post-IS, there was no gender difference in risk of mortality (Risk 1.12; 95% CI 0.98–1.27, n = 23,161).

Data from the subgroup analysis (Table 3) showed no gender difference in mortality in of women < 70 years after IS up to one-month from onset of stroke (in hospital, Risk 1.05; 0.69–1.60, n = 25,269; one month, Risk 1.41; 0.07–26.85, n = 91), however, women \geq 70 years had lower mortality risk compared to men (in hospital, Risk 0.94; 0.91–0.97, n = 768,707; one month, Risk 0.87; 0.77–0.98, n = 19,949).

Table 2

CASP quality assessment tool.

	Di Carlo, 2003	Olsen, 2010	Denti, 2013	Santalucia, 2013	Andersen, 2005	DeVries 2013	Olsen 2012	Wiszniewska 2011	Yang, 2004	Watila, 2012	Olsen, 2008	Oh, 2009	Vaartjes, 2009	Martinez- Sanchez, 2010	Wu, 2011	Renoux, 2017	Lewsey, 2012	Palnum, 2009	Vemmos,	Eriksson, 2021
Question assessed (Success rate)	•	N	N	Y	ο γ		N		Y	v	N	Y	-		V	7	• -	Υ	V	13 Y
1. Did the study address a clearly focused issue?	Y	Y	Y	Ŷ	Ŷ	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Ŷ	Y	Y
2. Was the cohort recruited in an acceptable way? (92.5%)	Y	Y	Y	N	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3. Was the exposure accurately measured to minimise bias? (85%)	Y	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	N	Y
4. Was the outcome accurately measured to minimise bias? (100%)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
5a. Have the authors identified all important confounding factors? (25%)	N	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	Y	N	Y	N	Y
b. Have they taken account of the confounding factors in the design and/or analysis? (47.5%)	Y	Y	Y	N	N	N	Y	N	N	Y	Y	N	N	N	N	Y	N	Y	N	Y
6a. Was the follow up of subjects complete enough? (67.5%)	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	N	Y	N
b. Was the follow up of subjects long enough? (70%)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y	N	Y	N
7.Are the results clearly presented? (97.5%) (clearly presented – Y/N)	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
8. Are the results precise? (85%)	Ν	Y	Y	Ν	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Ν	Y
9. Can the results be applied to the general population? (80%)	Y	Y	Y	N	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Total (/11):	9	10	10	4	8	8	10	9	9	8	10	9	8	10	8	9	8	9	7	9

	Barker-Collo 2015	Mapoure,	Kapral, 2005	Ovbiagele,	Hsieh,	lames, 2017	Koton,	Park, 2013	Li, 2015	owfig	iharm	Zhou, 2014	Talebi, 2014	iweile	Xing, 2	Dehlendorff, 2015	Weber, 2019	Bonkhoff,	lrie, 2021	Jchida	Phan,
	-Collo,	ure, 2017	, 2005	gele, 2011	2016	, 2017	, 2013	2013	б	Towfighi, 2011	Sharma, 2002	2014	2014	Sweileh, 2009	2017	ndorff,	; 2019	off, 2021)21	Uchida, 2019	2021
1. Did the study address a clearly focused issue?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	-	Y	Y
2. Was the cohort recruited in an acceptable way?	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	-	Y	Y
3. Was the exposure accurately measured to minimise bias?	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	-	Y	Y
4. Was the outcome accurately measured to minimise bias?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	-	Y	Y
5a. Have the authors identified all important confounding factors?	Ν	N	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	Y	N	Y	-	N	Y
b. Have they taken account of the confounding factors in the design and/or analysis?	Y	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	Y	Y	N	Y	-	Y	Y
6a. Was the follow up of subjects complete enough?	Y	Y	Y	Y	N	Y	Y	N	Y	Y	N	Y	N	N	Y	Y	Y	N	-	N	N
b. Was the follow up of subjects long enough?	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	Y	N	N	Y	Y	N	N	-	N	N
7.Are the results clearly presented? (clearly presented – Y/N)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	-	Y	Y
8. Are the results precise?	Ν	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Ν	Y	-	Y	Y
9. Can the results be applied to the general population?	Y	Y	Y	Y	N	Y	Y	N	N	Y	N	Y	Y	N	Y	Y	N	Y	-	Y	Y
Total (/11):	9	8	11	11	5	10	10	6	8	9	6	9	7	6	11	11	5	9	-	8	9

Table 3

Summary table of meta-analysis and subgroup analysis results illustrating risk of mortality in women, compared to men, up to one-month, 12-months and five-years after ischaemic (IS) and haemorrhagic stroke (HS) and stroke of unspecified type (SUT); Risk and corresponding 95% confidence intervals (CI) reported.

Sumn		from meta-analysis							
	Unadjusted	l mortality (Risk, 95	5% CI, sample size)			Adjusted mortality	(Risk, 95% CI, samp	le size)	
	In hospital		1-month	12-months	5-years	In hospital	1-month	12-months	5-years
IS	1.05 (1.03	, 1.07)	1.12 (0.98,	1.10 (1.06,	1.06 (1.02, 1.10)	0.94 (0.91, 0.97)	0.87 (0.77, 0.98)	0.94 (0.91,	0.93 (0.90,
	N = 1,903	,223	1.27)	1.14)	N = 50,119	N = 793,976	N = 20,040	0.98)	0.96)
			N = 23,161	N = 81,889				N = 63,255	N = 31,485
HS	1.04 (1.03	, 1.05) ^σ	1.09 (0.81,	95. (0.93,	95. (0.94, 1.07)	1.03 (1.01,	1.09 (0.70, 1.72)	0.97 (0.90,	0.96 (0.90,
	N = 192,82	26	1.47)	1.07)	N = 32,000	1.04) ^o	N = 1441	1.04)	1.02)∫
			N = 1441	N = 32,615		N = 192,826		N = 31,290	N = 30,675
SUT	0.98 (0.95	, 1.01)	1.11 (1.08,	1.11 (1.06,	1.02 (0.79, 1.32)	1.02 (1.00, 1.04)	0.98 (0.94, 1.04)	0.95 (0.90,	N/A
	N = 5,120	,945	1.15)	1.15)	ф	N = 5,254,065	N = 202,994	0.99)	
			N = 282,445	$N = 114,\!647$	N = 999			N = 120,145	
Subgr		s by age group					(21.1.0.20) 07		
	5	l mortality (Risk, 95	· · ·		_		(Risk, 95% CI, samp		_
	Mean	In hospital	1-month	12-months	5-years	In hospital	1-month	12-months	5-years
	Age	1 00 (1 00	1 1 4 (0 00	1 11 (1 01	1 07 (1 00 1 15)	1 05 (0 (0 1 (0)	1 41 (0 07		NY / 4
IS	< 70	1.22 (1.03,	1.14 (0.98,	1.11 (1.01,	1.07 (1.00, 1.15)	1.05 (0.69, 1.60)	1.41 (0.07,	N/A	N/A
		1.45)	1.32)	1.21)	N = 49,309	N = 25,269	26.85)		
	. 50	N = 25,269	N = 18,634	N = 49,309	0.00(0.0(1.01)	0.04(0.01.0.07)	N = 91	NT / A	NT / A
	≥70	1.05 (1.03,	1.07 (0.83,	1.03 (0.99,	0.98 (0.96, 1.01)	0.94 (0.91, 0.97)	0.87 (0.77, 0.98)	N/A	N/A
		1.07)	1.38)	1.06)	N = 31,485	N = 768,707	N = 19,949		
110	. 50	N = 1,907,954	N = 4527	N = 63,255	1 (0 (1 00 0 00)	NT / A	1 00 (0 (0 1 71)	1 15 (0 5(NT / A
HS	< 70	N/A	1.08 (0.79,	1.06 (0.83,	1.63 (1.20, 2.22)	N/A	1.09 (0.69, 1.71)	1.15 (0.56,	N/A
			1.46)	1.36)	N = 32,000		N = 1196	2.37)	
	. 50	NT / A	N = 1196	N = 49,309	0.00(0.00.1.00)	NT / A	1 (0 (0 0)	N = 615	NT / A
	≥70	N/A	1.30 (0.41,	0.96 (0.88,	0.98 (0.93, 1.03)	N/A	1.62 (0.06,	0.96 (0.90,	N/A
			4.14)	1.05)	N = 30,675		42.79)	1.03)	
01.07	. 50	0.00 (0.0(N = 245	N = 63,255	NT / A	0.00 (0.00 1.01)	N = 245	N = 30,675	NT / A
SUT	< 70	0.99 (0.96,	0.95 (0.82,	1.03 (0.85,	N/A	0.98 (0.96, 1.01)	1.03 (0.94, 1.13)	0.96 (0.79,	N/A
		1.02)	1.09)	1.23)		N = 187, 188	N = 5,248,664	1.16)	
	. 50	N = 133,238	N = 5,090,839	N = 29,549	NT / A	1 00 (1 01 1 05)	0.00 (0.04, 1.04)	N = 29,549	NI / A
	≥70	0.96 (0.92,	1.11 (1.08,	1.11 (1.06,	N/A	1.03 (1.01, 1.05)	0.98 (0.94, 1.04)	0.95 (0.90,	N/A
		1.00)	1.15)	1.15)		N = 202,994	N = 2,716,782	0.99)	
		N = 197,188	N = 2,583,848	N = 84,527				N = 79,029	

*IS= Ischaemic stroke, HS= Haemorrhagic stroke, SUT= Stroke of unspecified type, CI= confidence intervals.

^σResults available from one study only, James et al. [17].

^{\$}Results from one study only, Andersen et al. [14].

 \int Results from one study only, Vaartjes et al. [41].

No adjusted data were available beyond one-month post-IS. Crude data showed that women < 70 years were at higher risk of mortality post-IS up to five years after stroke (in hospital, Risk 1.22; 1.03–1.45, n = 25,269; 12 months Risk 1.11; 1.01–1.21, n = 49, 309; five years, Risk 1.07; 1.00–1.15, n = 49,309). However, apart from the in-hospital period, there was no difference in women \geq 70 years, compared to men, in mortality up to five years after IS.

3.5. Haemorrhagic stroke (HS)

Six studies reported data on HS-specific mortality between women and men. The analysis of data adjusted for confounding variables (detailed in Supplementary Table 1) showed that women had higher risk of mortality in hospital (Risk 1.03; 95% CI 1.01–1.04, n = 192,826) yet no difference was found after discharge and up to five years following discharge. Data from meta-analysis of unadjusted estimates yielded a similar result (in-hospital: Risk 1.04; 95% CI 1.03–1.05, n = 192,826) (Fig. 2).

Data from the subgroup analysis were consistent with adjusted and crude results from the primary analyses. The data show that there was no gender difference in mortality after HS in both the < 70 years and \geq 70 years groups. No in-hospital data were available for HS patients to compare with the primary analysis findings.

3.6. Stroke of unspecified type (SUT)

Seventeen studies reported on mortality after stroke without specifying stroke type. Analysis of adjusted data (Table 3) showed higher mortality risk in women during the in-hospital period (Risk 1.02; 95% CI 1.00–1.04, n = 5,254,065), however, lower risk after one-month (up to 12-months) (Risk 0.95; 95% CI 0.90–0.99, n = 120,145) post-SUT (Fig. 3). No gender difference was found in the first month after discharge (Risk 0.98; 95% CI: 0.94–1.04, n = 202,99).

On the other hand, meta-analysis of crude data showed no gender difference in risk of mortality was found in-hospital (Risk 0.98; 95% CI 0.95–1.01, n = 5,120,945), however higher mortality risk up-to one-month (Risk 1.11; 95% CI 1.06–1.15, n = 114,647) and 12-months post-SUT (Risk 1.11; 95% CI 1.06–1.15, n = 114,644).

Results from the subgroup analysis of patients after SUT were consistent with the primary analysis for subjects \geq 70 years. Compared to men, women in this group had higher mortality in-hospital (Risk 1.03; 1.01–1.05, n = 202,994) however, lower mortality after one-month post-SUT (Risk 0.95; 0.90–0.99, n = 79,029). In women < 70 years, there was no difference in mortality from stroke onset through to 12-months. No adjusted data were available beyond 12-months follow-up post-SUT.

Crude data showed no gender difference after SUT in the < 70 years age group. On the other hand, consistent with the primary analysis,

A) In-hospital mortality

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
25.1.1 In-hospital m	ortality post-IS (Unadjusted)			
Bonkhoff, 2021	0.06069784	0.01530612	14.1%	1.06 [1.03, 1.09]	•
Oh, 2009	0.21748394	0.09693878	0.4%	1.24 [1.03, 1.50]	-
Ong, 2017	0.29907126	0.1744898	0.1%	1.35 [0.96, 1.90]	
Park, 2012	0.13353891	0.18877551	0.1%	1.14 [0.79, 1.65]	
Weber, 2019	0.04099769	0.0125	21.1%	1.04 [1.02, 1.07]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)			35.7%	1.05 [1.03, 1.07]	1
Heterogeneity: Chi ² =	6.20, df = 4 (P =	0.18 ; $I^2 = 35$	%		
Test for overall effect	Z = 5.36 (P < 0.0)	00001)			
25.1.2 <70 years (U	nadjusted)				
Oh, 2009	0.21748394	0.09693878	0.4%	1.24 [1.03, 1.50]	
Park, 2012		0.18877551		1.14 [0.79, 1.65]	
Subtotal (95% CI)				1.22 [1.03, 1.45]	
Heterogeneity: Chi ² =	0.16. df = 1 (P =	0.69 ; $I^2 = 0$?	5		ŀ
Test for overall effect					
25.1.3 ≥70 years (U	nadiusted)				
Bonkhoff, 2021		0.01530612	14.1%	1.06 [1.03, 1.09]	h.
Ong, 2017	0.29907126			1.35 [0.96, 1.90]	
Weber, 2019	0.04099769	0.0125		1.04 [1.02, 1.07]	
Subtotal (95% CI)	0.04055705	0.0120		1.05 [1.03, 1.07]	
Heterogeneity: Chi ² =	3.04. df = 2 (P =	0.22 ; $I^2 = 34$			ľ
Test for overall effect					
25.1.4 In-hospital m	ortality post-IS (Adjusted)			
Bonkhoff, 2021	-0.06550155	0.01530612	14.1%	0.94 [0.91, 0.97]	-
Kapral, 2004	0.00518051	0.21352041	0.1%	1.01 [0.66, 1.53]	
Oh, 2009	0.09342169	0.62	0.0%	1.10 [0.33, 3.70]	•
Ong, 2017	0.05307844	0.32397959	0.0%	1.05 [0.56, 1.99]	
Park, 2012	0.04139269	0.22959184		1.04 [0.66, 1.63]	
Subtotal (95% CI)				0.94 [0.91, 0.97]	•
Heterogeneity: Chi ² =			5		
Test for overall effect	: Z = 4.23 (P < 0.0	0001)			
25.1.5 <70 years (Ad	djusted)				
Oh, 2009	0.09342169	0.62		1.10 [0.33, 3.70]	•
Park, 2012	0.04139269	0.22959184		1.04 [0.66, 1.63]	
Subtotal (95% CI)		-		1.05 [0.69, 1.60]	•
Heterogeneity: Chi ² =			5		
Test for overall effect	Z = 0.22 (P = 0.8)	32)			
25.1.6 ≥70 years (A	djusted)				
Bonkhoff, 2021	-0.06550155	0.01530612	14.1%	0.94 [0.91, 0.97]	•
Kapral, 2004	0.00518051	0.21352041	0.1%	1.01 [0.66, 1.53]	
Ong, 2017 Subtotal (95% CI)	0.05307844	0.32397959		1.05 [0.56, 1.99] 0.94 [0.91, 0.97]	
Heterogeneity: Chi ² =	0.24. df = 2 (P =	(0.89) ; $I^2 = 09$			'
Test for overall effect			r		
Total (95% CI)			100.0%	1.02 [1.01, 1.03]	
Heterogeneity: Chi2 =	96.34, df = 19 (P	< 0.00001);	$^{2} = 80\%$		
Test for overall effect					0.1 0.2 0.5 1 2 5 10
Test for subgroup dif		,	P < 0.000	01), $I^2 = 94.2\%$	Favours [Women] Favours [Men]

*IS= Ischaemic stroke

Fig. 1. Forest plots of meta-analysis and subgroup analysis results for mortality in women, compared to men, after ischaemic stroke (IS); Risk and corresponding 95% confidence intervals (CI) reported.

B) Mortality up to one-month

			Risk Ratio	Risk Ratio
Study or Subgroup		Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
23.1.1 Up-to-1mth p	oost-IS (Unadjusted)			
Denti, 2013	0.06069784 0.16836735	3.6%	1.06 [0.76, 1.48]	+
Oh, 2009	0.12839927 0.07806122		1.14 [0.98, 1.32]	*
Wiszniewska, 2010	0.07918125 0.19642857			-
Subtotal (95% CI)		23.1%	1.12 [0.98, 1.27]	•
,	0.16, df = 2 (P = 0.92); $I^2 = 0.92$	6		
Test for overall effect:	Z = 1.68 (P = 0.09)			
23.1.2 <70 years (Un	adjusted)			
Oh, 2009	0.12839927 0.07806122	16.8%	1.14 [0.98, 1.32]	-
Subtotal (95% CI)		16.8%		•
Heterogeneity: Not ap	plicable			
Test for overall effect:				
22.1.2 > 70 was a (1)	a diverse d			
23.1.3 ≥70 years (Un	•	2.6%	1 06 [0 76 1 49]	L
Denti, 2013 Wiszniewska, 2010	0.06069784 0.16836735 0.07918125 0.19642857		1.06 [0.76, 1.48] 1.08 [0.74, 1.59]	—
Subtotal (95% CI)	0.07918125 0.19042857	6.3%		L
	0.01, df = 1 (P = 0.94); $I^2 = 0.94$		100 [0005] 1007	T
Test for overall effect:		*		
rest for orenan enece.	2 - 0.51 (0 - 0.55)			
23.1.4 Up-to-1mth p	oost-IS (Adjusted)			
Denti, 2013	-0.18708664 0.10459184	9.4%	0.83 [0.68, 1.02]	-
Irie, 2021	-0.11918641 0.07653061	17.5%	0.89 [0.76, 1.03]	-
Watila, 2012 Subtotal (95% CI)	0.34044411 1.50510204		1.41 [0.07, 26.85] 0.87 [0.77, 0.98]	•
Heterogeneity: Chi ² =	0.38, df = 2 (P = 0.83); $I^2 = 0.000$	6		
Test for overall effect:	Z = 2.30 (P = 0.02)			
23.1.5 <70 years (Ad	(insted)			
Watila, 2012	0.34044411 1.50510204	0.0%	1.41 [0.07, 26.85]	
Subtotal (95% CI)	0.34044411 1.30310204		1.41 [0.07, 26.85]	
Heterogeneity: Not ap	plicable			
Test for overall effect:				
23.1.6 ≥70 years (Ad	-			
Denti, 2013	-0.18708664 0.10459184			-
Irie, 2021	-0.11918641 0.07653061			7
Subtotal (95% CI)		26.9%	0.87 [0.77, 0.98]	•
	0.27, df = 1 (P = 0.60); $I^2 = 0.02$	6		
Test for overall effect:	z = 2.31 (P = 0.02)			
Total (95% CI)		100.0%	0.98 [0.92, 1.04]	•
(16.75, df = 11 (P = 0.12); I ² =			
Test for overall effect:				0.01 0.1 1 10 100 Favours [Women] Favours [Men]
	ferences: Chi ² = 15.93, df = 5 (P = 0.007	7), $I^2 = 68.6\%$	ravours (women) ravours (men)

*IS= Ischaemic stroke

Fig. 1. (continued).

C) Mortality up to 12-months

	-			Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]		Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
24.1.1 Up-to-12mth	is post-IS (Unadj	usted)			
Li, 2015	0.49831055	1.48979592	0.0%	1.65 [0.09, 30.52]	
Oh, 2009	0.10788803	0.04745918	4.9%	1.11 [1.01, 1.22]	*
Olsen, 2012	0.15745677	0.04081633	6.7%	1.17 [1.08, 1.27]	*
Renoux, 2017	0.12057393	0.07908163	1.8%	1.13 [0.97, 1.32]	-
Uchida, 2019	0.10720997	0.16836735	0.4%	1.11 [0.80, 1.55]	+
Vaartjes, 2009	0.06069784	0.0255102	17.1%	1.06 [1.01, 1.12]	
Subtotal (95% CI)			30.8%	1.10 [1.06, 1.14]	,
Heterogeneity: Chi ² =					
Test for overall effect	Z = 4.91 (P < 0.0)	00001)			
24.1.2 <70 years (Ur	•				
Oh, 2009		0.04745918	4.9%	1.11 [1.01, 1.22]	
Vaartjes, 2009	0.05690485	0.13010204	0.7%	1.06 [0.82, 1.37]	
Subtotal (95% CI)			5.6%	1.11 [1.01, 1.21]	•
Heterogeneity: Chi ² =					
Test for overall effect	Z = 2.29 (P = 0.0)	02)			
2412 270					
24.1.3 ≥70 years (Ur					
Li, 2015		1.48979592		1.65 [0.09, 30.52]	
Olsen, 2012		0.04081633	6.7%	1.17 [1.08, 1.27]	
Renoux, 2017		0.07908163	1.8%	1.13 [0.97, 1.32]	
Uchida, 2019		0.16836735	0.4%	1.11 [0.80, 1.55]	
Vaartjes, 2009 Subtotal (95% CI)	-0.026872	0.022959	21.1% 29.9%	0.97 [0.93, 1.02] 1.03 [0.99, 1.06]	
Heterogeneity: Chi ² =	17 44 46 4 (0	0.000) 12		1.05 [0.99, 1.00]	
Test for overall effect			1176		
rest for overall effect	$\Sigma = 1.29 (F = 0.7)$	20)			
24.1.4 Up-to-12mth	s post-IS (Adjust	ted)			
Li. 2015	0.50105926	1.5255102	0.0%	1.65 [0.08, 32.82]	
Olsen, 2012	-0.05551733			0.95 [0.83, 1.07]	
Renoux, 2017	-0.08618615		3.5%	• • •	
Uchida, 2019		0.11989796	0.8%		
Vaartjes, 2009	-0.05551733		26.7%		
Subtotal (95% CI)			33.7%		
Heterogeneity: Chi ² =	0.57, df = 4 (P =	0.97 ; $I^2 = 0\%$			1
Test for overall effect	,				
Total (95% CI)			100.0%	1.02 [1.00, 1.04]	
Heterogeneity: Chi ² =			$^{2} = 72\%$		0.01 0.1 1 10 100
Test for overall effect					Favours [Women] Favours [Men]
Test for subgroup dif	ferences: Chi ² = 3	7.66, df = 3 (F	P < 0.000	01), $I^2 = 92.0\%$	

*IS= Ischaemic stroke

Fig. 1. (continued).

D) Mortality up to five-years

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Fixed, 95% CI	I IV, Fixed, 95% CI
26.1.1 Up-to-5yrs p	ost-IS (Unadjust	ed)			
Li, 2015	0.54654266	2.18367347	0.0%	1.73 [0.02, 124.77]]
Oh, 2009	0.07954301	0.03979592	4.5%	1.08 [1.00, 1.17]	1 •
Vaartjes, 2009 Subtotal (95% CI)	0.05307844	0.02040816	16.9% 21.4%	1.05 [1.01, 1.10] 1.06 [1.02, 1.10]	
Heterogeneity: Chi ² =	0.40, df = 2 (P =	0.82 ; $I^2 = 0\%$			
Test for overall effect	Z = 3.23 (P = 0.0)	001)			
26.1.2 <70 years (Ur	nadiusted)				
Oh. 2009	-	0.03979592	4.5%	1.08 [1.00, 1.17]	1
Vaarties, 2009		0.1071428	0.6%	1.00 [0.81, 1.24]	
Subtotal (95% CI)			5.1%	1.07 [1.00, 1.15]	
Heterogeneity: Chi ² =	0.43, df = 1 (P =	0.51 ; $I^2 = 0\%$			
Test for overall effect	Z = 1.89 (P = 0.0)	06)			
26.1.3 ≥70 years (Ur	nadjusted)				
Li, 2015	0.54654266	2.18367347	0.0%	1.73 [0.02, 124.77]]
Vaartjes, 2009 Subtotal (95% CI)	-0.0177287	0.0127551	43.4% 43.4%	0.98 [0.96, 1.01] 0.98 [0.96, 1.01]	
Heterogeneity: Chi ² =	0.07, df = 1 (P =	0.80); $I^2 = 0\%$			
Test for overall effect	Z = 1.39 (P = 0.2)	17)			
26.1.4 Up-to-5yrs p	ost–IS (Adjusted))			
Li, 2015	0.53147892	2.19387755	0.0%	1.70 [0.02, 125.39]]
Vaartjes, 2009	-0.07058107	0.01530612	30.1%	0.93 [0.90, 0.96]	
Subtotal (95% CI)			30.1%	0.93 [0.90, 0.96]	1 1
Heterogeneity: Chi ² =					
Test for overall effect	Z = 4.61 (P < 0.0)	00001)			
Total (95% CI)			100.0%	0.99 [0.97, 1.00]	1
Heterogeneity: Chi ² =			= 78%		0.01 0.1 1 10 100
Test for overall effect					Favours [Women] Favours [Men]
Test for subgroup dif	ferences: Chi ² = 3	4.83, df = 3 (F	? < 0.000	01), $I^2 = 91.4\%$	

*IS= Ischaemic stroke

Fig. 1. (continued).

A) In-hospital mortality

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
27.1.1 In-hospital m	nortality post-HS	(Unadjusted)			
James, 2017 Subtotal (95% CI)	0.04099769	0.00637755	53.8% 53.8%	1.04 [1.03, 1.05] 1.04 [1.03, 1.05]	+
Heterogeneity: Not ap	plicable				
Test for overall effect:	Z = 6.43 (P < 0.1)	00001)			
27.1.2 In-hospital m	nortality post-HS	(Adjusted)			
James, 2017 Subtotal (95% CI)	0.02694163	0.00688776	46.2% 46.2%	1.03 [1.01, 1.04] 1.03 [1.01, 1.04]	↓
Heterogeneity: Not ap	plicable				
Test for overall effect:	Z = 3.91 (P < 0.1)	0001)			
Total (95% CI)			100.0%	1.04 [1.03, 1.04]	◆
Heterogeneity: Chi ² =	2.24, df = 1 (P =	0.13 ; $I^2 = 55$	%		0.85 0.9 1 1.1 1.2
Test for overall effect:	Z = 7.37 (P < 0.1)	00001)			Favours [Women] Favours [Men]
Test for subgroup diff	ferences: $Chi^2 = 2$.	.24, df = 1 (P =	= 0.13), I	² = 55.4%	ravours (monicity Tavours [men]

*HS= Haemorrhagic stroke

**Results available from one study only; James et al., 2017.

B) Mortality up to one-month

			Risk Ratio	Risk Ratio
		Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
28.1.1 Up-to-1mth pe	ost-HS (Unadjusted)			
Ganti, 2013	0.26481782 0.58928571			
Hsieh, 2016	0.07554696 0.15561224			
Subtotal (95% CI)		35.0%	1.09 [0.81, 1.47]	†
Test for overall effect:	0.10, df = 1 (P = 0.76); $I^2 = 0$ 7 = 0.58 (P = 0.56)	%		
rest for overall effect.	2 = 0.38 (r = 0.30)			
28.1.2 <70 years (Una	adjusted)			
Hsieh, 2016 Subtotal (95% CI)	0.07554696 0.15561224	32.7% 32.7%		
Heterogeneity: Not app				
Test for overall effect:	Z = 0.49 (P = 0.63)			
28.1.3 ≥70 years (Una	diusted)			
Ganti, 2013	0.26481782 0.58928571	2.3%	1.30 [0.41, 4.14]	
Subtotal (95% CI)	0.20401702 0.50520571	2.3%		
Heterogeneity: Not app	olicable			
Test for overall effect:	Z = 0.45 (P = 0.65)			
28.1.4 Up-to-1mth p	ost_HS (Adjusted)			
Ganti, 2013	0.48144263 1.67091837	0.3%	1.62 [0.06, 42.79]	
Hsieh, 2016	0.08278537 0.23214857			
Subtotal (95% CI)		15.0%		
	0.06, df = 1 (P = 0.81); $I^2 = 0$	%		
Test for overall effect:	Z = 0.39 (P = 0.69)			
28.1.5 <70 years (Adj	usted)			
Hsieh, 2016	0.08278537 0.23214857	14.7%	1.09 [0.69, 1.71]	
Subtotal (95% CI)		14.7%	1.09 [0.69, 1.71]	+
Heterogeneity: Not app				
Test for overall effect:	Z = 0.36 (P = 0.72)			
28.1.6 ≥70 years (Adj	usted)			
Ganti, 2013	0.48144263 1.67091837	0.3%	1.62 [0.06, 42.79]	
Subtotal (95% CI)		0.3%	1.62 [0.06, 42.79]	
Heterogeneity: Not app				
Test for overall effect:	Z = 0.29 (P = 0.77)			
Total (95% CI)		100.0%	1.09 [0.92, 1.30]	•
	0.30, df = 7 (P = 1.00); $I^2 = 0$			
Test for overall effect:	Z = 1.00 (P = 0.32)			0.01 0.1 1 10 100 Favours (Women) Favours (Men)
Test for subgroup diffe	erences: $Chi^2 = 0.15$, $df = 5$ (F	P = 1.00),	$I^2 = 0\%$	rated is [women] rated is [men]

*HS= Haemorrhagic stroke

Fig. 2. Forest plots of meta-analysis and subgroup analysis results for mortality in women, compared to men, after haemorrhagic stroke (HS); Risk and corresponding 95% confidence intervals (CI) reported.

C) Mortality up to 12-months

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]		Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
29.1.1 Up-to-12mth	s post-HS (Unadj	justed)			
Vaartjes, 2009	-0.00436481	0.03826531	24.0%	1.00 [0.92, 1.07]	+
Xing, 2017	0.1271048	0.25510204	0.5%	1.14 [0.69, 1.87]	
Zhou, 2014	0	0.18877551		1.00 [0.69, 1.45]	
Subtotal (95% CI)				1.00 [0.93, 1.07]	•
Heterogeneity: Chi ² =					
Test for overall effect:	Z = 0.04 (P = 0.9)	97)			
29.1.2 <70 years (Un	adjusted)				
Vaartjes, 2009	0.09691001	0.2346939	0.6%	1.10 [0.70, 1.75]	.
Xing, 2017	0.1271048	0.25510204		1.14 [0.69, 1.87]	
Zhou, 2014	0	0.18877551	1.0%	1.00 [0.69, 1.45]	
Subtotal (95% CI)			2.2%	1.06 [0.83, 1.36]	+
Heterogeneity: Chi ² =					
Test for overall effect:	Z = 0.47 (P = 0.6)	54)			
29.1.3 ≥70 years (Un	adjusted)				
Vaartjes, 2009	-0.0409586	0.0459184	16.7%	0.96 [0.88, 1.05]	+
Subtotal (95% CI)			16.7%	0.96 [0.88, 1.05]	4
Heterogeneity: Not ap					
Test for overall effect:	Z = 0.89 (P = 0.3)	37)			
29.1.4 Up-to-12mth	s post–HS (Adjus	ted)			
Vaartjes, 2009	-0.03621217	0.03571429	27.6%	0.96 [0.90, 1.03]	+
Zhou, 2014	0.13987909	0.36989796		1.15 [0.56, 2.37]	
Subtotal (95% CI)				0.97 [0.90, 1.04]	•
Heterogeneity: Chi ² =	, , ,				
Test for overall effect:	Z = 0.97 (P = 0.3)	33)			
29.1.5 <70 years (Ad	ljusted)				
Zhou, 2014	0.13987909	0.36989796		1.15 [0.56, 2.37]	
Subtotal (95% CI)			0.3%	1.15 [0.56, 2.37]	
Heterogeneity: Not ap					
Test for overall effect:	Z = 0.38 (P = 0.7)	71)			
29.1.6 ≥70 years (Ad	ljusted)				
Vaartjes, 2009	-0.03621217	0.03571429	27.6%	0.96 [0.90, 1.03]	+
Subtotal (95% CI)			27.6%	0.96 [0.90, 1.03]	4
Heterogeneity: Not ap					
Test for overall effect:	Z = 1.01 (P = 0.3)	31)			
Total (95% CI)			100.0%	0.98 [0.94, 1.01]	
Heterogeneity: Chi ² =	2.02, df = 10 (P =	$= 1.00$; $I^2 = 0$			0.1 0.2 0.5 1 2 5 10
Test for overall effect:		0.1 0.2 0.5 1 2 5 10 Favours [Women] Favours [Men]			
Test for subgroup diff	ferences: Chi ² = 1	.34, $df = 5$ (P	= 0.93),	$1^2 = 0\%$	rated as [fremen] rated as [men]

*HS= Haemorrhagic stroke

Fig. 2. (continued).

D) Mortality up to five-years


				Risk Ratio	Risk Ratio				
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI				
30.1.1 Up-to-5yrs p	ost-HS (Unadjusted)								
Vaartjes, 2009	0.00432137 0.0	3316327	26.6%	1.00 [0.94, 1.07]	+				
Xing, 2017	0.08278537 0.2	3214286		1.09 [0.69, 1.71]					
Subtotal (95% CI)				1.01 [0.94, 1.07]	•				
	= 0.11, df = 1 (P = 0.7)	4); $I^2 = 0\%$							
Test for overall effect	Z = 0.18 (P = 0.86)								
30.1.2 <70 years (U	nadiusted)								
Vaartjes, 2009	0.827853 0.2	1173460	0.7%	2.29 [1.51, 3.47]					
Xing, 2017	0.08278537 0.2			1.09 [0.69, 1.71]					
Subtotal (95% CI)	0.00270557 0.2	5214200		1.63 [1.20, 2.22]	•				
	= 5.62, df = 1 (P = 0.0)	2): $I^2 = 829$			-				
	Z = 3.13 (P = 0.002)								
30.1.3 ≥70 years (U	nadjusted)								
Vaartjes, 2009	-0.01772876 0.	0255102		0.98 [0.93, 1.03]	•				
Subtotal (95% CI)			45.0%	0.98 [0.93, 1.03]	•				
Heterogeneity: Not ap									
Test for overall effect	Z = 0.69 (P = 0.49)								
30.1.4 Up-to-5yrs p	ost–HS (Adiusted)								
Vaarties, 2009	-0.04095861 0.0	3316327	26.6%	0.96 [0.90, 1.02]	-				
Subtotal (95% CI)				0.96 [0.90, 1.02]	•				
Heterogeneity: Not an	oplicable								
Test for overall effect									
Total (95% CI)				0.99 [0.96, 1.02]					
	Heterogeneity: $Chi^2 = 17.12$, $df = 5$ (P = 0.004); $l^2 = 71\%$								
Test for overall effect					Favours [Women] Favours [Men]				
Test for subgroup dif	ferences: Chi ² = 11.39	9, df = 3 (P	P = 0.010), $I^2 = 73.7\%$					

*HS= Haemorrhagic stroke

**Adjusted results available from one study only; Vaartjes et al., 2009

Fig. 2. (continued).

A) In-hospital mortality



*SUT= Stroke of unspecified type

Fig. 3. Forest plots of meta-analysis and subgroup analysis results for mortality in women, compared to men, after stroke of unspecified type (SUT); Risk and corresponding 95% confidence intervals (CI) reported.

B) Mortality up to one-month

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE We	iaht	IV, Fixed, 95% CI	
	post-SUT (Unadjusted		. <u>.</u>		
Dehlendorff, 2015	0.1417632 0.02		2 3%	1.15 [1.09, 1.22]	
Di Carlo, 2003	0.09096308 0.08			1.10 [0.92, 1.30]	
Olsen, 2007	0.1383027 0.03			1.15 [1.08, 1.23]	
Olsen, 2009	0.03462846 0.07			1.04 [0.89, 1.21]	
Palnum, 2009	0.0211893 0.05			1.02 [0.92, 1.13]	
Wu 2012	0.05690485 0.04			1.06 [0.97, 1.16]	
Subtotal (95% CI)				1.11 [1.08, 1.15]	
Heterogeneity: Chi ² =	7.08, df = 5 (P = 0.21)	; I ² = 29%			
	Z = 6.23 (P < 0.00001				
32.1.2 <70 years (Un	nadjusted)				
Palnum, 2009	0.0374265 0.	107143	0.8%	1.04 [0.84, 1.28]	-
Wu 2012	-0.1249387 0.09			0.88 [0.73, 1.06]	
Subtotal (95% CI)			1.9%	0.95 [0.82, 1.09]	•
	1.29, df = 1 (P = 0.26)	; I ² = 23%			
Test for overall effect:	Z = 0.76 (P = 0.45)				
22.1.2 > 70	and in stand)				
32.1.3 ≥70 years (Un		000133	3.24	1 15 (1 66 1 22)	-
Dehlendorff, 2015	0.1417632 0.02			1.15 [1.09, 1.22]	
Di Carlo, 2003	0.09096308 0.08			1.10 [0.92, 1.30]	
Olsen, 2007	0.1383027 0.03			1.15 [1.08, 1.23]	
Olsen, 2009 Palnum, 2009	0.03462846 0.07 0.0211893 0.05			1.04 [0.89, 1.21] 1.02 [0.92, 1.13]	
Wu 2012	0.05690485 0.04			1.06 [0.97, 1.16]	
Subtotal (95% CI)	0.03090483 0.04			1.11 [1.08, 1.15]	
	7.08, df = 5 (P = 0.21)		2.070		'
	: Z = 6.23 (P < 0.00001				
rest for overall effect					
32.1.4 Up-to-1mth p	post-SUT (Adjusted)				
DeVries, 2011	0.06032003 0.05	841837	2.8%	1.06 [0.95, 1.19]	+-
Lewsey, 2012	0.0374265 0.03	571429	7.6%	1.04 [0.97, 1.11]	+
Palnum, 2009	-0.14874165 0.04	591837	4.6%	0.86 [0.79, 0.94]	-
Subtotal (95% CI)		1	5.0%	0.98 [0.94, 1.04]	•
	12.30, df = 2 (P = 0.0	02); I ² = 84%			
Test for overall effect:	Z = 0.60 (P = 0.55)				
32.1.5 <70 years (Ad	-				
Lewsey, 2012	0.0413927 0.05			1.04 [0.94, 1.15]	
Palnum, 2009	-0.0409586 0.1			0.96 [0.77, 1.20]	
Subtotal (95% CI)	0.45 +4 - 1 (0 - 0.50)		4.3%	1.03 [0.94, 1.13]	Ť
	0.45, df = 1 (P = 0.50)	$1^{\circ} = 0\%$			
Test for overall effect:	$\Sigma = 0.59 (P = 0.50)$				
32.1.6 ≥70 years (Ad	ljusted)				
DeVries, 2011	0.06032003 0.05	841837	2.8%	1.06 [0.95, 1.19]	
Lewsey, 2012	0.0374265 0.03			1.04 [0.97, 1.11]	
Palnum, 2009	-0.14874165 0.04			0.86 [0.79, 0.94]	
Subtotal (95% CI)				0.98 [0.94, 1.04]	
Heterogeneity: Chi ² =	12.30, df = 2 (P = 0.0	02); $I^2 = 84\%$			
Test for overall effect					
					l.
Total (95% CI)				1.07 [1.05, 1.09]	
	76.38, df = 21 (P < 0.		73%		0,1 0,2 0,5 1 2 5 10
	Z = 6.58 (P < 0.0000)	-			Favours [Women] Favours [Men]
Test for subgroup diff	ferences: Chi ² = 35.88,	df = 5 (P < 0)	0.000	$(01), I^2 = 86.1\%$	

*SUT= Stroke of unspecified type

Fig. 3. (continued).


C) Mortality up to 12-months

				Risk Ratio	Risk Ratio
Study or Subgroup Id	g[Risk Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
33.1.1 Up-to-12mths p		djusted)			
Andersen, 2005	0.07040732	0.13775502	0.7%	1.07 [0.82, 1.41]	
Di Carlo, 2003	0.10311925	0.0744898	2.4%	1.11 [0.96, 1.28]	+-
Olsen, 2007	0.1172713	0.02704082	18.4%	1.12 [1.07, 1.19]	-
Palnum, 2009	0.03342376	0.04846939	5.7%	1.03 [0.94, 1.14]	+
Phan, 2021	0.21748394	0.125	0.9%	1.24 [0.97, 1.59]	
Vemmos, 2000	0.09691001	0.17857143	0.4%	1.10 [0.78, 1.56]	
Subtotal (95% CI)			28.5%	1.11 [1.06, 1.15]	•
Heterogeneity: Chi ² = 3. Test for overall effect: Z					
33.1.2 <70 years (Unad	ljusted)				
Palnum, 2009	0.02530587	0.09438776		1.03 [0.85, 1.23]	
Subtotal (95% CI)			1.5%	1.03 [0.85, 1.23]	•
Heterogeneity: Not appli Test for overall effect: Z		'9)			
33.1.3 ≥70 years (Unad	justed)				
Andersen, 2005	0.07040732	0.13775502	0.7%	1.07 [0.82, 1.41]	
Di Carlo, 2003	0.10311925			1.11 [0.96, 1.28]	
Olsen, 2007		0.02704082		1.12 [1.07, 1.19]	
Palnum, 2009	0.03342376	0.04846939		1.03 [0.94, 1.14]	
Phan, 2021	0.21748394	0.125		1.24 [0.97, 1.59]	
Vemmos, 2000	0.09691001	0.17857143		1.10 [0.78, 1.56]	
Subtotal (95% CI)				1.11 [1.06, 1.15]	
Heterogeneity: Chi ² = 3.	22, df = 5 (P =	0.67 ; $I^2 = 0\%$			
Test for overall effect: Z	= 4.64 (P < 0.0	0001)			
33.1.4 Up-to-12mths p	ost-SUT (Adju	sted)			
Koton, 2013	-0.02227639	0.3	0.1%	0.98 [0.54, 1.76]	
Olsen, 2007	-0.03791492	0.03548469	10.7%	0.96 [0.90, 1.03]	+
Palnum, 2009	-0.11350927	0.04336735	7.1%	0.89 [0.82, 0.97]	-
Phan, 2021	0.07554696	0.09693878	1.4%	1.08 [0.89, 1.30]	
Vemmos, 2000 Subtotal (95% CI)	-0.03621217	0.14030612		0.96 [0.73, 1.27] 0.95 [0.90, 0.99]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z					
33.1.5 <70 years (Adju:		0.00503077	1 40-	0.05 (0.70. 3.15)	
Palnum, 2009 Subtotal (95% CI)	-0.04575749	0.09693877		0.96 [0.79, 1.16] 0.96 [0.79, 1.16]	
Heterogeneity: Not appli Test for overall effect: Z		(4)			
33.1.6 ≥70 years (Adju	sted)				
Koton, 2013	-0.02227639	0.3	0.1%	0.98 [0.54, 1.76]	
Olsen, 2007	-0.03791492			0.96 [0.90, 1.03]	
Palnum, 2009	-0.11350927			0.89 [0.82, 0.97]	
Phan, 2021	0.07554696			1.08 [0.89, 1.30]	
Vemmos, 2000	-0.03621217			0.96 [0.73, 1.27]	
Subtotal (95% CI)				0.95 [0.90, 0.99]	
Heterogeneity: Chi ² = 3.	89, df = 4 (P =	0.42 ; $I^2 = 0\%$			
Test for overall effect: Z					
Total (95% CI)			100.0%	1.04 [1.01, 1.06]	
Heterogeneity: Chi ² = 58	8.36, df = 23 (P	< 0.0001); I ²	= 61%		0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z					0.1 0.2 0.5 1 2 5 10 Favours [Women] Favours [Men]
Test for subgroup different	ences: Chi ² = 44	4.13, df = 5 (F	P < 0.000	01), $I^2 = 88.7\%$. arous fromen, rarous frient

*SUT= Stroke of unspecified type

Fig. 3. (continued).

D) Mortality up to five-years



*SUT= Stroke of unspecified type

**Results available from one study only; Andersen et al., 2005. No data available for adjusted data on up to five-years mortality after stroke of unspecified type (SUT).

Fig. 3. (continued).

women \geq 70 years had higher mortality after one and 12-months post-SUT (one-month: Risk 0.96; 0.92–1.00, n = 2,583,848; 12 months: Risk 1.11; 1.06, 1.15, n = 84,527).

4. Discussion

The results of our systematic review provide robust evidence that there are important gender differences in medium- and long-term mortality after stroke, which are dependent on stroke type and length of follow-up. After ischaemic stroke, women consistently had lower risk of mortality than men, ranging from 6% in-hospital to 13% lower risk by one-month and 7% by five years, after adjusting for important confounders, such as: age, history of previous strokes, hypertension, hyperlipidaemia, atrial fibrillation, ischaemic heart disease. Nevertheless, meta-analysis of unadjusted estimates showed up to 10% higher mortality post-IS in women at all follow-up points, suggesting that this higher raw mortality is mostly explained by gender-based characteristics of female stroke patients, such as higher age at stroke onset and prevalence of comorbidities.

The results of our age-stratified subgroup analysis show that older women (\geq 70 years) had a lower mortality after IS compared to men, however this gender difference was not apparent in younger women (<70 years). Unadjusted data appears to unmask the higher mortality in women compared to men regardless of age group. These findings support current literature which suggests that age-adjusted data may obscure the complex relationship of sex differences at specific ages [2].

A retrospective analysis of participants from the International Stroke Trial (IST) showed a higher raw mortality 24.5% in women (24.5%) compared to in men (19.3%) at six-months [45]. However, when they adjusted for age, stroke severity, atrial fibrillation, and blood pressure, women had lower mortality at six months (OR 0.90; 95% CI 0.83–0.98). Other previous studies also yielded similar findings of higher post-stroke raw mortality in women, but lower mortality after adjustment for relevant confounders [2,3].

Two important conclusions pertaining to gender equity in stroke care can be drawn from this study. Firstly, the higher stroke mortality in women is unlikely to be driven independently by intrinsic biological differences in stroke pathophysiology, but largely by age as well as comorbid disease burden. Thereby, it is essential to recognise that the differences in raw mortality seen in routine clinical practice can be reduced by changes in clinical practice, namely; better primary prevention of comorbidities including cardiovascular disease and smoking cessation as well as more tailored clinical management of these comorbidities in women.

In terms of HS, it can be concluded that beyond discharge, no gender difference appears between the risks of mortality of women and men after a HS, irrespective of confounders or age group. Our data is concordant with that of one study which concluded no gender differences in unadjusted or adjusted risk of mortality risk irrespective of confounding (OR 1.19; 95% CI 0.92–1.53 and OR 0.188; 95% CI 0.84–1.75), respectively [28]. Nevertheless, more studies assessing risk of mortality in women compared to men post-HS are crucial for more robust evidence.

Cellular-level investigations into the role of cell-death pathways and inflammatory signalling cascades, influenced by the effects of oestrogen in women, appear to provide some basis to the gender-specific biology of ischaemia in IS. One study highlighted that the neuroprotection offered by higher levels of oestrogen in women as well as slowing large artery atherosclerosis build-up [46]. Although these studies suggest women have less severe strokes, it is important to highlight that lack of adjustment for stroke subtype, severity and comorbidities is an important notable limitation of these studies.

Geographical, racial and socio-economic factors are also important to highlight as potential confounders to differences in stroke mortality between women and men. Excess stroke mortality in women is of particular concern in Asian populations, where there are clear differences in patient biology and epidemiology documented in the literature compared to Western populations [19,47,48]. The prevalence of intracranial plaques causing IS has been reported as 38.5% in Caucasians compared to 69.1% in Chinese populations (p = 0.02) [19]. Large racial-ethnic disparities in Black and Hispanic individuals compared to white individuals have also been highlighted in the literature [51]. In these populations, the higher rates of stroke mortality, particularly in women, were due to key geopolitical and economic factors including: poorer health literacy, a large

AR.	Abdel-Fattah	et	al.
-----	--------------	----	-----

Table 4

Studies included in meta-analysis of gender differences in stroke mortality; by geographical region.

Region	No. of studies	Name of study	No. of participants (%) Total= 8, 008, 110
USA and Canada	5	James, 2017	5, 302, 794 (66.2%)
		DeVries, 2011	
		Ovbiagele, 2011	
		Towfighi, 2011	
		Kapral, 2004	
Europe	16	Bonkhoff, 2021	2, 532, 686 (31.6%)
-		Eriksson, 2021	
		Weber, 2019	
		Renoux, 2017	
		Denti, 2013	
		Santalucia, 2013	
		Lewsey, 2012	
		Olsen, 2012	
		Wiszniewska, 2010	
		Palnum, 2009	
		Olsen, 2009	
		Vaartjes, 2009	
		Olsen, 2007	
		Andersen, 2005	
		Di Carlo, 2003	
		Vemmos, 2000	
East Asia	10	Irie, 2021	157, 537 (1.97%)
		Uchida, 2021	
		Ong, 2017	
		Xing, 2017	
		Hsieh, 2016	
		Li, 2015	
		Zhou, 2014	
		Park, 2012	
		Wu, 2012	
		Oh, 2009	
Australia	1	Phan, 2021	9441 (0.12%)
Africa	1	Watila, 2012	91 (0.0011%)
Middle East	2	Sweileh, 2009	527 (0.0066%)
Luot	2	Talebi, 2014	027 (0.000070)
Near East	1	Koton, 2013	5034 (0.063%)
Worldwide	1	Ganti, 2013	245 (0.0031%)

gender pay gap resulting in lower income and poorer healthcare affordability in women, differences in socio-economic status and differing beliefs [49,53] in African countries, unique barriers to the provision of quality stroke care include a shortage of medical transport, specialist staff and well-equipped stroke units, economic recessions resulting in inability to support the cost of brain imaging, thrombolysis or out-patient rehabilitation. These reasons are responsible for inter-continental disparities in stroke care and outcomes [51].

Due to the wide distribution of the included studies across the globe, analysing data from specific regions by time period or stroke type was not possible due to insufficient data for pooling (Table 5). In addition, as shown in Table 4, the Western hemisphere represents 98% (n = 7, 835,

Table 5

Names and population of studies for age-stratified subgroup analysis of gender differences in stroke mortality: mean age < 70 years and >or= 70 years.

Follow-up time period	Ischaemic stroke			
	< 70 years		\geq 70 years	
	Unadjusted	Adjusted	Unadjusted	Adjusted
In-hospital mortality	Oh, 2009	Oh, 2009	Bonkhoff, 2021	Bonkhoff, 2021
	Park, 2012	Park, 2012	Weber, 2019	Kapral, 2004
			Ong, 2017	Ong, 2017
No. of participants ($N = $)	N = 25,269	N = 25,269	N = 1,907,954	N = 768,707
Up to 1 month	Oh, 2009	Watila, 2012	Denti, 2013	Denti, 2013
			Wiszniewskwa, 2010	Irie, 2021
No. of participants ($N = $)	N = 18,634	N = 91	N = 4527	N = 19,949
Up to 12 months	Oh, 2009	_	Li, 2015	-
	Vaartjes, 2009 *		Olsen, 2012	
			Renoux, 2017	
			Uchida, 2019	
			Vaartjes, 2009 *	
No. of participants ($N = $)	N = 49,309	_	N = 63,255	-
Up to 5 years	Oh, 2009	_	Li, 2015	-
	Vaartjes, 2009 *		Vaartjes, 2009 *	
No. of participants ($N = $)	N = 49,309	_	N = 31,485	-
Haemorrhagic stroke				
	< 70 years		\geq 70 years	
	Unadjusted	Adjusted	Unadjusted	Adjusted

(continued on next page)

A.-R. Abdel-Fattah et al.

Table 5 (continued)

Table 5 (continued)				
In-hospital mortality	_	_	_	-
Up to 1 month	Hsieh, 2016	Hsieh, 2016	Ganti, 2013	Ganti, 2013
No. of participants ($N = $)	N = 1196	N = 1196	N = 245	N-245
Up to 12 months	Vaartjes, 2009 *	Zhou, 2014	Vaartjes, 2009 *	Vaartjes, 2009 *
	Xing, 2017			
	Zhou, 2014			
No. of participants ($N = $)	N = 49,309	N = 615	N = 63,255	N = 30,675
Up to 5 years	Vaartjes, 2009 *	_	Vaartjes, 2009 *	_
	Xing, 2017			
No. of participants ($N = $)	N = 32,000	_	N = 30,675	_
Stroke of unspecified type (SUT)				
	< 70 years		\geq 70 years	
	Unadjusted	Adjusted	Unadjusted	Adjusted
In-hospital mortality	Palnum, 2009 *	Lewsey, 2012 *	Lewsey, 2012 *	DeVries, 2011
	Wu, 2012 *	Palnum, 2009 *	Palnum, 2012 *	Lewsey, 2012 *
				Palnum, 2009 *
No. of participants ($N = $)	N = 133,238	N = 187,188	N = 197,188	N = 202,994
Up to 1 month	Ovbiagele, 2011 *	Lewsey, 2012 *	Di Carlo, 2003	Koton, 2013
	Towfighi, 2010	Ovbiagele, 2011 *	Olsen, 2009	Lewsey, 2012 *
		Sweileh, 2009	Ovbiagele, 2011 *	Ovbiagele, 2011 *
		Towfighi, 2010		Santalucia, 2013
No. of participants ($N = $)	N = 5,090,839	N = 5,248,664	N = 2,583,848	N = 2,716,782
Up to 12 months	Palnum, 2009 *	Palnum, 2009 *	Andersen, 2015	Koton, 2013
			Di Carlo, 2003	Olsen, 2007
			Olsen, 2007	Palnum, 2009 *
			Palnum, 2009 *	Phan, 2021
			Phan, 2021	Vemmos, 2000
			Vemmos, 2000	
No. of participants ($N = $)	N = 29,549	N = 29,549	N = 84,527	N = 79,029
Up to 5 years	-	-	-	-

*Age-stratified data was available in the paper and extracted for subgroup analysis (see Supplementary Tables 3-6 for age-stratified data).

480/8, 008, 110) of the participants in the meta-analysis, whist Eastern Asia, Africa and Middle/Near East combined represent 2% (n = 172, 630) of the participants. Therefore, an analysis by geographical region would be statistically underpowered and therefore add little value to our findings.

This comprehensive systematic review and meta-analysis has a number of strengths. It presents the most up-to-date evidence from observational studies comparing risk of mortality between women and men after IS and HS, from diagnosis to five-years follow up. The participants of the studies represented a large demographic spread from various different healthcare systems which increases the generalisability and global applicability of our findings. All literature searches, data extraction, meta-analysis and quality appraisal were put through a rigorous cross-check by at least two independent researchers at every stage. There are also some limitations worth highlighting. There was a high degree of heterogeneity in the variables that were adjusted for as well as a lack of adjustment of stroke severity. Further, the majority of studies in the current literature are those with Western study cohorts. Therefore, it is important to note that East Asia and Africa are underrepresented in the existing analysis and would be statistically underpowered if analysis was stratified by region. In addition, there was an inadequate number of studies available to meta-analyse results at individual post-operative follow-up time points therefore, time brackets were utilised.

Clinicians treating stroke patients must be cognisant of the important risk factors including age, HTN and AF which put women at higher risk of mortality than men. Equally however, they should understand that this relationship is an interplay of various confounding factors that when adjusted for, women have a lower risk of mortality than men post-IS. Finally, it is important to recognise the lack of evidence surrounding the gender differences in risk of mortality following HS and the necessity of further research for haemorrhagic aetiology of stroke.

5. Conclusion

The gender differences in mortality risk after stroke is dependent on stroke type, age group and duration since stroke onset. Crude stroke mortality in women was found to be higher than in men however this appears to be driven by pre-existing comorbidities. The current literature suggests that once age, stroke severity and comorbidities are adjusted for, women were at lower risk of mortality, compared to men following IS, irrespective of time. In HS, beyond the in-hospital period where women are at higher risk of mortality, there is no gender difference in mortality risk. Further research pertaining to gender differences specifically after HS is warranted to better understand this relationship. Appropriate prevention and management of IS in women is paramount to ensuring gender equity in the provision of stroke care.

Funding

AA received the Leslie Wilson Aberdeen Summer Research Scholarship (ASRS) to carry out the research (Grant ID: CF-10114-15).

Conflict of interest

None declared.

CRediT authorship contribution statement

Abdel-Rahman Abdel-Fattah: Primary reviewer, Literature review, Data-analysis and Drafting manuscript. Tiberiu A. Pana: Statistical analysis and Supervision, Drafting manuscript. Toby O. Smith: Senior reviewer for systematic review, Supervision of systematic review, drafting manuscript. Zahra Pasdar: Second data extraction, Drafting manuscript. Maha Aslam: Second reviewer, Drafting manuscript. Mamas A. Mamas: Supervision, Critical revision. Phyo K. Myint: Supervision, Senior reviewer, Critical revision, Guarantor.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.clineuro.2022.107359.

References

- A.A. Samai, S. Martin-Schild, Sex differences in predictors of ischemic stroke: current perspectives, Vasc. Health Risk Manag, 11 (2015) 427–436.
- [2] H.T. Phan, C.L. Blizzard, M.J. Reeves, A.G. Thrift, D. Cadilhac, J. Sturm, E. Heeley, P. Otahal, V. Konstantinos, C. Anderson, P. Parmar, R. Krishnamurthi, S. Barker-Collo, V. Feigin, Y. Bejot, N.L. Cabral, A. Carolei, S. Sacco, N. Chausson, S. Olindo, P. Rothwell, C. Silva, M. Correia, R. Magalhães, P. Appelros, J. Körv, R. Vibo, C. Minelli, S. Gall, Sex differences in long-term mortality after stroke in the INSTRUCT (INternational STRoke oUtComes sTudy): a meta-analysis of individual participant data, Circ. Cardiovasc Qual. Outcomes 10 (2) (2017), e003436, https:// doi.org/10.1161/CIRCOUTCOMES.116.003436.
- [3] A.K. Bonkhoff, A. Karch, R. Weber, J. Wellmann, K. Berger, Female stroke: sex differences in acute treatment and early outcomes of acute ischemic stroke, Stroke 52 (2) (2021) 406–415, https://doi.org/10.1161/STROKEAHA.120.032850.
- [4] F. Irie, R. Matsuo, K. Nakamura, Y. Wakisaka, T. Ago, M. Kamouchi, T. Kitazono, Fukuoka Stroke Registry Investigators, Sex differences in the risk of 30-day death after acute ischemic stroke, Neurol. Clin. Pract. 11 (6) (2021) e809–e816, https:// doi.org/10.1212/CPJ.00000000001087.
- [5] M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ 372 (2021) n71, https://doi.org/10.1136/bmj.
- [6] R. Weber, C. Krogias, J. Eyding, D. Bartig, S.H. Meves, A.H. Katsanos, V. Caso, W. Hacke, Age and sex differences in ischemic stroke treatment in a nationwide analysis of 1.11 million hospitalized cases, Stroke 50 (12) (2019) 3494–3502, https://doi.org/10.1161/STROKEAHA.119.026723.
- [7] M. Eriksson, S. Åsberg, K.S. Sunnerhagen, M. von Euler, Sex differences in stroke care and outcome 2005-2018: observations from the Swedish stroke register, Stroke 52 (10) (2021) 3233–3242, https://doi.org/10.1161/ STROKEAHA.120.033893.
- [8] C. Dehlendorff, K.K. Andersen, T.S. Olsen, Sex disparities in stroke: women have more severe strokes but better survival than men, J. Am. Heart Assoc. 4 (7) (2015), e001967, https://doi.org/10.1161/JAHA.115.001967.
- [9] Zorana Jovanovic Andersen, Tom Skyhøj Olsen, Andersen Klaus Kaae, Explaining poorer stroke outcomes in women: women surviving 3 months have more severe strokes than men despite a lower 3-month case fatality, Gend. Med. 9 (3) (2012) 147–153, https://doi.org/10.1016/j.genm.2012.03.002.
- [10] Klaus Kaae Andersen, Tom Skyhøj Olsen, Female survival advantage relates to male inferiority rather than female superiority: a hypothesis based on the impact of age and stroke severity on 1-week to 1-year case fatality in 40,155 men and women, Gend. Med. 7 (4) (2010) 284–295, https://doi.org/10.1016/j.genm.2010.08.001.
- [11] T.S. Olsen, C. Dehlendorff, K.K. Andersen, The female stroke survival advantage: relation to age, Neuroepidemiology 32 (1) (2009) 47–52, https://doi.org/10.1159/ 000170906. Epub 2008 Nov 12.
- [12] T.S. Olsen, C. Dehlendorff, K.K. Andersen, Sex-related time-dependent variations in post-stroke survival-evidence of a female stroke survival advantage, Neuroepidemiology 29 (3–4) (2007) 218–225, https://doi.org/10.1159/ 000112464.
- [13] K.D. Palnum, G. Andersen, A. Ingeman, B.R. Krog, P. Bartels, S.P. Johnsen, Sexrelated differences in quality of care and short-term mortality among patients with acute stroke in Denmark: a nationwide follow-up study, Stroke 40 (4) (2009) 1134–1139, https://doi.org/10.1161/STROKEAHA.108.543819.
- [14] M.N. Andersen, K.K. Andersen, L.P. Kammersgaard, T.S. Olsen, Sex differences in stroke survival: 10-year follow-up of the Copenhagen stroke study cohort, J. Stroke Cereb. Dis. 14 (2005) 215–220.
- [15] K. Uchida, S. Yoshimura, N. Sakai, H. Yamagami, T. Morimoto, Sex differences in management and outcomes of acute ischemic stroke with large vessel occlusion, Stroke 50 (7) (2019) 1915–1918, https://doi.org/10.1161/ STROKEAHA.119.025344.
- [16] H.T. Phan, S. Gall, C.L. Blizzard, N.A. Lannin, A.G. Thrift, C.S. Anderson, J. Kim, R. Grimley, H.C. Castley, M.F. Kilkenny, D.A. Cadilhac, Sex differences in causes of death after stroke: evidence from a national, prospective registry, J. Women's. Health 30 (3) (2021) 314–323, https://doi.org/10.1089/jwh.2020.8391.
- [17] M.L. James, M. Cox, Y. Xian, et al., Sex and age interactions and differences in outcomes after intracerebral hemorrhage, J. Women's Health 26 (4) (2017) 380–388, https://doi.org/10.1089/jwh.2016.5849.
- [18] D. DeVries, Y. Zhang, M. Qu, J. Ma, G. Lin, Gender difference in stroke case fatality: an integrated study of hospitalization and mortality, J. Stroke Cereb. Dis. 22 (7) (2013) 931–937, https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.10.011.

- [19] B. Ovbiagele, D. Markovic, A. Towfighi, Recent age- and gender-specific trends in mortality during stroke hospitalization in the united states, Int. J. Stroke 6 (5) (2011) 379–387, https://doi.org/10.1111/j.1747-4949.2011.00590.x.
- [20] A. Towfighi, W. Tai, D. Markovic, B. Ovbiagele, Sex-specific temporal trends in inhospital mortality after stroke among middle-age individuals in the united states, Stroke 42 (10) (2011) 2740–2745, https://doi.org/10.1161/ STROKEAHA.110.612648.
- [21] M.K. Kapral, J. Fang, M.D. Hill, et al., Sex differences in stroke care and outcomes: results from the registry of the canadian stroke network, Stroke 36 (4) (2005) 809–814.
- [22] Y.N. Mapoure, N.L. Eyambe, A.T. Dzudie, et al., Gender-related differences and short-term outcome of stroke: results from a hospital-based registry in Sub-Saharan Africa, Neuroepidemiology 49 (3–4) (2017) 179–188, https://doi.org/10.1159/ 000484319.
- [23] C. Ong, Y. Wong, S. Sung, et al., Sex-related differences in the risk factors for inhospital mortality and outcomes of ischemic stroke patients in rural areas of taiwan, PLoS One 12 (9) (2017), e0185361, https://doi.org/10.1371/journal. pone.0185361.
- [24] Y. Xing, Z. An, X. Zhang, et al., Sex differences in the clinical features, risk factors, and outcomes of intracerebral hemorrhage: a large hospital-based stroke registry in china, Sci. Rep. 7 (2017) 286, https://doi.org/10.1038/s41598-017-00383-6.
- [25] B. Li, T. Wang, Y. Lou, et al., Sex differences in outcomes and associated risk factors after acute ischemic stroke in elderly patients: a prospective follow-up study, J. Stroke Cerebrovasc. Dis. 24 (10) (2015) 2277–2284.
- [26] J. Zhou, Y. Zhang, H. Arima, et al., Sex differences in clinical characteristics and outcomes after intracerebral hemorrhage: results from a 12-month prospective stroke registry in Nanjing, China, BMC Neurol. 14 (1) (2014).
- [27] S.H. Wu, S.C. Ho, P.H. Chau, W. Goggins, A. Sham, J. Woo, Sex differences in stroke incidence and survival in hong kong, 2000-2007, Neuroepidemiology 38 (2) (2012) 69–75, https://doi.org/10.1159/000335040.
- [28] J.T. Hsieh, B.T. Ang, Y.P. Ng, J.C. Allen, N.K.K. King, Comparison of gender differences in intracerebral hemorrhage in a multi-ethnic asian population, PLoS ONE 11 (4) (2016), e0152945, https://doi.org/10.1371/journal.pone.0152945.
- [29] M. Talebi, M. Ghertasi, A. Taheraghdam, S. Andalib, E. Sharifipour, A comparison of risk factors and severity of ischemic stroke in female and male genders in northwest iran: a cross-sectional study, Iran. J. Neurol. 13 (4) (2014) 215–219.
- [30] L. Denti, A. Artoni, U. Scoditti, et al., Impact of gender-age interaction on the outcome of ischemic stroke in an italian cohort of patients treated according to a standardized clinical pathway, Eur. J. Intern. Med. 24 (8) (2013) 807–812, https:// doi.org/10.1016/j.ejim.2013.07.015.
- [31] P. Santalucia, F.R. Pezzella, M. Sessa, S. Monaco, G. Torgano, S. Anticoli, E. Zanoli, M. Maimone Baronello, M. Paciaroni, V. Caso, Women Stroke Association (WSA), Sex differences in clinical presentation, severity and outcome of stroke: results from a hospital-based registry, Eur. J. Intern. Med. 24 (2) (2013) 167–171, https:// doi.org/10.1016/j.ejim.2012.10.004.
- [32] Silvia Telman Koton, Kimiagar Gregory, David Itzhak Tanne, Gender differences in characteristics, management and outcome at discharge and three months after stroke in a national acute stroke registry, Int. J. Cardiol. 168 (4) (2013) 4081–4084, https://doi.org/10.1016/j.ijcard.2013.07.019.
 [33] J.D. Lewsey, M. Gillies, P.S. Jhund, J.W. Chalmers, A. Redpath, A. Briggs,
- [33] J.D. Lewsey, M. Gillies, P.S. Jhund, J.W. Chalmers, A. Redpath, A. Briggs, M. Walters, P. Langhorne, S. Capewell, J.J. McMurray, K. Macintyre, Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005, Stroke 40 (4) (2009) 1038–1043, https://doi.org/ 10.1161/STROKEAHA.108.542787.
- [34] C. Renoux, J. Coulombe, L. Li, A. Ganesh, L. Silver, P.M. Rothwell, Oxford vascular study. confounding by pre-morbid functional status in studies of apparent sex differences in severity and outcome of stroke, Stroke 48 (10) (2017) 2731–2738, https://doi.org/10.1161/STROKEAHA.117.018187.
- [35] S.J. Park, S.D. Shin, Y.S. Ro, K.J. Song, J. Oh, Gender differences in emergency stroke care and hospital outcome in acute ischemic stroke: a multicenter observational study, Am. J. Emerg. Med. 31 (1) (2013) 178–184, https://doi.org/ 10.1016/j.ajem.2012.07.004.
- [36] M. Oh, K. Yu, J. Roh, B. Lee, Korean Stroke Registry Study Group, Gender differences in the mortality and outcome of stroke patients in korea, Cereb. Dis. 28 (5) (2009) 427–434, https://doi.org/10.1159/000235986.
- [37] M.M. Watila, Y.W. Nyandaiti, A. Ibrahim, I.D. Gezawa, S.A. Bwala, Sex-related differences in stroke outcome at a university of maiduguri teaching hospital, northeastern nigeria, J. Neurol. 259 (2012) S19–S199.
- [38] P. Martinez-Sanchez, B. Fuentes, J. Fernandez-Dominguez, et al., Young women have poorer outcomes than men after stroke, Cereb. Dis. 31 (5) (2011) 455–463, https://doi.org/10.1159/000323851.
- [39] M. Wiszniewska, M. Niewada, A. Czlonkowska, Sex differences in risk factor distribution, severity, and outcome of ischemic stroke, Acta Clin. Croat. 50 (1) (2011) 21–28.
- [40] W.M. Sweileh, A.F. Sawalha, S.M. Al-Aqad, S.H. Zyoud, S.W. Al-Jabi, Predictors of in-hospital mortality after acute stroke: impact of gender, Int. J. Clin. Exp. Med. 2 (1) (2009) 41–47.
- [41] I. Vaartjes, J.B. Reitsma, M. Berger-van Sijl, Bots ML. Gender differences in mortality after hospital admission for stroke, Cereb. Dis. 28 (6) (2009) 564–571, https://doi.org/10.1159/000247600.
- [42] K.N. Vemmos, M.L. Bots, P.K. Tsibouris, V.P. Zis, C.E. Takis, D.E. Grobbee, S. Stamatelopoulos, Prognosis of stroke in the south of Greece: 1 year mortality, functional outcome and its determinants: the Arcadia Stroke Registry, J. Neurol. Neurosurg. Psychiatry 69 (5) (2000) 595–600, https://doi.org/10.1136/ jnnp.69.5.595.

- [43] A. Di Carlo, M. Lamassa, M. Baldereschi, et al., Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in europe: data from a multicenter multinational hospital-based registry, Stroke 34 (5) (2003) 1114–1119, https://doi.org/10.1161/01.STR.0000068410.07397.D7.
- [44] L. Ganti, A. Jain, N. Yerragondu, M. Jain, M.F. Bellolio, R.M. Gilmore, A. Rabinstein, Female gender remains an independent risk factor for poor outcome after acute nontraumatic intracerebral hemorrhage, Neurol. Res. Int. 2013 (2013), 219097, https://doi.org/10.1155/2013/219097.
- [45] M. Niewada, A. Kobayashi, P.A. Sandercock, B. Kamiński, A. Członkowska, International Stroke Trial Collaborative Group. Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trial, Neuroepidemiology 24 (3) (2005) 123–128, https://doi.org/10.1159/000082999.
- [46] M.S. Spychala, P. Honarpisheh, L.D. McCullough, Sex differences in neuroinflammation and neuroprotection in ischemic stroke, J. Neurosci. Res. 95 (1–2) (2017) 462–471, https://doi.org/10.1002/jnr.23962.
- [47] R. Petrea, A. Beiser, S. Seshadri, et al., Gender differences in stroke incidence and poststroke disability in the Framingham heart study, Stroke 40 (2009) 1032–1037, https://doi.org/10.1161/STROKEAHA.108.542894.
- [48] M. Kapral, N. Degani, R. Hall, et al., Gender differences in stroke care and outcomes in Ontario, Women's Health Issues 21 (2011) 171–176, https://doi.org/ 10.1016/j.whi.2010.10.002.

- [49] P. Thorvaldsen, K. Kuulasmaa, A. Rajakangas, et al., Stroke trends in the WHO MONICA project, Stroke 28 (1997) 500–506, https://doi.org/10.1161/01. str.28.3.500.
- [50] S. Das, T. Banerjee, A. Biswas, et al., A prospective community-based study of stroke in Kolkata, India, Stroke 38 (2007) 906–910, https://doi.org/10.1161/01. STR.0000258111.00319.58.
- [51] J. Woo, E. Lau, R. Kay, Elderly subjects aged 70 years and above have different risk factors for ischemic and hemorrhagic strokes compared to younger subjects, J. Am. Geriatr. Soc. 40 (2) (1992) 124–129, https://doi.org/10.1111/j.1532-5415.1992. tb01931.x.
- [52] G. Urimubenshi, D. Cadilhac, J. Kagwiza, et al., Stroke care in Africa: a systematic review of the literature, Int. J. Stroke 13 (8) (2018) 797–805, https://doi.org/ 10.1177/1747493018772747.
- [53] S. Cruz-Flores, A. Rabinstein, J. Biller, et al., American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke 42 (7) (2011) 2091–2116, https://doi.org/10.1161/ STR.0b013e3182213e24.